Measurable Residual Disease in Pediatric Acute Leukemia: Application and Interpretation of Current and Emerging Methodologies
American Society of Clinical Oncology Educational Book · 2026-06 · 46 (3)
DOI: 10.1200/edbk-26-516962 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2026-06. Verfasst von Lisa Eidenschink Brodersen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA. Hauptthemen laut MEDLINE: Neoplasm, Residual, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 123 Literaturangaben.
Abstract (Originalsprache)
Measurable/minimal residual disease (MRD) monitoring is an essential component of modern treatment protocols for ALL and AML. Early response to therapy, as measured by MRD levels at defined time points during treatment, serves as an important prognostic indicator and enables risk-adapted stratification with intensification of treatment for patients with poor response while potentially reducing therapy-related toxicity in those demonstrating excellent clearance of leukemic cells. MRD assays must be highly sensitive and specific; multidimensional/parameter flow cytometry (MFC), quantitative polymerase chain reaction (qPCR), and next generation sequencing (NGS) are most used, while morphology is no longer the gold standard of response. MRD by MFC is used globally for risk and response in ALL and AML and is applicable to nearly 100% of patients with a sensitivity of 10 −4 . For ALL, immunoglobulin/T-cell receptor rearrangements detected by qPCR or NGS offer a nearly universal target applicable to more than 90% of patients with B-ALL and up to 70% of patients with T-ALL with a sensitivity of 10 −5 . For AML, molecular testing is more frequently implemented in Europe and Asia than in the United States; however, the utilization of qPCR and/or digital droplet PCR (dPCR) methodologies for high-risk fusions is evolving. NGS for somatic mutations are not yet routinely implemented for risk or response in pediatric AML, but continued advances in NGS technologies will continue to transform the MRD landscape of pediatric leukemias.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA.
- University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
- Departments of Laboratory Medicine and Pathology, Boston Children's Hospital, Boston, MA.
- Harvard Medical School, Boston, MA.
- Childhood Leukaemia Investigation Prague, Prague, Czech Republic.
- Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
ORCID-Profile: Lisa Eidenschink Brodersen, Jan Zuna
Zitieren
APA
Eidenschink Brodersen, L., Kovach, A. E., & Zuna, J. (2026). Measurable Residual Disease in Pediatric Acute Leukemia: Application and Interpretation of Current and Emerging Methodologies. American Society of Clinical Oncology Educational Book, 46(3). https://doi.org/10.1200/edbk-26-516962
Vancouver
Eidenschink Brodersen L, Kovach AE, Zuna J. Measurable Residual Disease in Pediatric Acute Leukemia: Application and Interpretation of Current and Emerging Methodologies. American Society of Clinical Oncology Educational Book. 2026;46(3). doi:10.1200/edbk-26-516962
BibTeX
@article{EidenschinkBrodersen2026,
author = {Eidenschink Brodersen, Lisa and Kovach, Alexandra E and Zuna, Jan},
title = {Measurable Residual Disease in Pediatric Acute Leukemia: Application and Interpretation of Current and Emerging Methodologies},
journal = {American Society of Clinical Oncology Educational Book},
year = {2026},
volume = {46},
number = {3},
doi = {10.1200/edbk-26-516962}
}
EUVIMED